Roche launches cobas® 5800, a new diagnostics system to expand access to testing and improv

JOHANNESBURG - Jan. 19, 2022 - PRLog -- Roche today announced the launch of the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Testing is one of the first lines of defence to protect a patient's general well-being and is vitally important in quickly guiding their treatment. The cobas® 5800 System helps address challenges that laboratories are facing from an increase in patient testing, reimbursement complexities and the need for a more diverse testing menu while providing meaningful and timely results.

"The cobas® 5800 System is a potential gateway to access where it is needed the most. Patients in Africa face barriers to access throughout their healthcare journey. Among the most pressing barriers are awareness, diagnostics, funding and healthcare capacity,¹ said Sandra Orta, Corporate General Manager South Africa & Head of Management Center Sub-Saharan Africa Roche Diagnostics.

Orta adds, "We are pleased that we can now offer a compact, fully-automated molecular system to help address the high demands on labs through greater efficiency, optimised workflows and cost savings, enabling them to deliver quality patient care and doing now what patients need next."

The cobas® 5800 system, the newest member of the Roche Molecular Work Area, is built upon the innovation of the cobas® 6800 and cobas® 8800 systems, making molecular testing accessible to more patients around the world.

Roche anticipates receiving U.S. Food and Drug Administration approval during Q3 2022.